FDA Alert - Drug Safety Communication: Celexa (citalopram hydrobromide) - Abnormal Heart Rhythms Associated With High Doses

Sent to you from Drugs.com You received this email because you are subscribed to updates from Drugs.com. Change your notification settings or unsubscribe here.

FDA MedWatch Alert Sent to subscribers of: citalopram systemic Drug Safety Communication: Celexa (citalopram hydrobromide) - Abnormal Heart Rhythms Associated With High Doses August 24, 2011 Audience: Psychiatry, Cardiology. ISSUE: FDA notified healthcare professionals and patients that the antidepressant Celexa (citalopram hydrobromide) should no longer be used at doses greater than 40 mg per day because it can cause abnormal changes in the electrical activity of the heart. Changes in the electrical activity of the heart (prolongation of the QT interval of the electrocardiogram [ECG]) can lead to an abnormal heart rhythm (including Torsade de Pointes), which can be fatal. Patients at particular risk for developing prolongation of the QT interval include those with underlying heart conditions and those who are predisposed to low levels of potassium and magnesium in the blood. Read more... Get these updates via twitter

Copyright © 2011 Drugs.com. All rights reserved. You received this email because you are subscribed to updates from Drugs.com. Change your notification settings or unsubscribe here.